Search

Daniel R Scoles

from Holladay, UT
Age ~62

Daniel Scoles Phones & Addresses

  • 4797 Ichabod St, Salt Lake City, UT 84117 (310) 642-9540
  • Holladay, UT
  • 17613 Calvert St, Encino, CA 91316 (818) 996-1428 (310) 280-0508
  • Gloucester Point, VA
  • 10882 Rose St, Los Angeles, CA 90034 (310) 280-0508
  • Columbia, SC

Work

Company: University of utah school of medicine Position: Associate professor of neurology

Industries

Higher Education

Resumes

Resumes

Daniel Scoles Photo 1

Associate Professor Of Neurology

View page
Location:
Salt Lake City, UT
Industry:
Higher Education
Work:
University of Utah School of Medicine
Associate Professor of Neurology

Publications

Us Patents

Schwannomin-Binding Proteins

View page
US Patent:
6960650, Nov 1, 2005
Filed:
Apr 4, 2002
Appl. No.:
10/117604
Inventors:
Stefan M. Pulst - Los Angeles CA, US
Daniel R. Scoles - Los Angeles CA, US
Assignee:
Cedars-Sinai Medical Center - Los Angeles CA
International Classification:
C07H021/02
C07H021/04
C07K014/435
US Classification:
530350, 530395, 530397, 536 231, 536 235
Abstract:
In accordance with the present invention, there are provided novel Schwannomin-Binding-Proteins (SBPs). Nucleic acid sequences encoding such proteins and assays employing same are also disclosed. The invention SBPs can be employed in a variety of ways, for example, for the production of anti-SBP antibodies thereto, in therapeutic compositions and methods employing such proteins and/or antibodies. Also provided are transgenic non-human mammals that express the invention protein.

Nucleic Acid Encoding Schwannomin-Binding-Proteins And Products Related Thereto

View page
US Patent:
20060199195, Sep 7, 2006
Filed:
Nov 1, 2005
Appl. No.:
11/265560
Inventors:
Stefan Pulst - Los Angeles CA, US
Daniel Scoles - Los Angeles CA, US
International Classification:
C12Q 1/68
C07H 21/04
C12P 21/06
C07K 14/705
US Classification:
435006000, 435069100, 435320100, 435325000, 530350000, 536023500
Abstract:
In accordance with the present invention, there are provided novel Schwannomin-Binding-Proteins (SBPs). Nucleic acid sequences encoding such proteins and assays employing same are also disclosed. The invention SBPs can be employed in a variety of ways, for example, for the production of anti-SBP antibodies thereto, in therapeutic compositions and methods employing such proteins and/or antibodies. Also provided are transgenic non-human mammals that express the invention protein.

Nucleic Acid Encoding Schwannomin-Binding-Proteins And Products Related Thereto

View page
US Patent:
6376174, Apr 23, 2002
Filed:
Nov 14, 1997
Appl. No.:
08/971089
Inventors:
Stefan M. Pulst - Los Angeles CA
Daniel R. Scoles - Los Angeles CA
Assignee:
Cedars-Sinai Medical Center - Los Angeles CA
International Classification:
C12Q 168
US Classification:
435 6, 435 691, 435 711, 4352523, 4353201, 435455, 536 231, 536 235, 536 2431, 536 2433, 514 44
Abstract:
In accordance with the present invention, there are provided novel Schwannomin-Binding-Proteins (SBPs). Nucleic acid sequences encoding such proteins and assays employing same are also disclosed. The invention SBPs can be employed in a variety of ways, for example, for the production of anti-SBP antibodies thereto, in therapeutic compositions and methods employing such proteins and/or antibodies. Also provided are transgenic non-human mammals that express the invention protein.

Staufen1 Regulating Agents And Associated Methods

View page
US Patent:
20210238590, Aug 5, 2021
Filed:
Jun 14, 2019
Appl. No.:
15/734174
Inventors:
- Salt Lake City UT, US
Daniel R. Scoles - Salt Lake City UT, US
Sharan Paul - Salt Lake City UT, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
C12N 15/113
A61K 45/06
Abstract:
Methods of minimizing dysregulation of Staufen1-associated RNA metabolism can include introducing an amount of a Staufen1-regulating agent to a target cell sufficient to minimize the dysregulation. Therapeutic compositions for treating a neurodegenerative condition associated with Staufen1-induced dysregulation of RNA metabolism can include a therapeutically effective amount of a Staufen1-regulating agent and a pharmaceutically acceptable carrier.

Staufen1 Agents And Associated Methods

View page
US Patent:
20200069721, Mar 5, 2020
Filed:
Dec 8, 2017
Appl. No.:
16/467945
Inventors:
- Salt Lake City UT, US
Daniel R. Scoles - Salt Lake City UT, US
Sharan Paul - Salt Lake City UT, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
A61K 31/713
A61K 45/06
A61P 25/28
C12N 15/113
Abstract:
Methods of minimizing dysregulation of Staufen1-associated RNA metabolism can include introducing an amount of a Staufen1 -regulating agent to a target cell sufficient to minimize the dysregulation. Therapeutic compositions for treating a neurodegenerative condition associated with Staufen1-induced dysregulation of RNA metabolism can include a therapeutically effective amount of a Staufen1-regulating agent and a pharmaceutically acceptable carrier.

Methods For Modulating Ataxin 2 Expression

View page
US Patent:
20190017047, Jan 17, 2019
Filed:
May 7, 2018
Appl. No.:
15/973088
Inventors:
- Carlsbad CA, US
- Salt Lake City UT, US
Stefan M. Pulst - Salt Lake City UT, US
Daniel R. Scoles - Salt Lake City UT, US
Gene Hung - San Diego CA, US
Assignee:
Ionis Pharmaceuticals, Inc. - Carlsbad CA
University of Utah Research Foundation - Salt Lake City UT
International Classification:
C12N 15/113
Abstract:
Disclosed herein are methods for decreasing Ataxin 2 mRNA and protein expression. Such methods are useful to treat, prevent, or ameliorate Ataxin 2 associated diseases, disorders, and conditions. Such Ataxin 2 associated diseases include spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), and parkinsonism.

Methods For Modulating Ataxin 2 Expression

View page
US Patent:
20170175113, Jun 22, 2017
Filed:
Mar 19, 2015
Appl. No.:
15/127352
Inventors:
- Carlsbad CA, US
- Salt Lake City CT, US
Stefan M. Pulst - Salt Lake City UT, US
Daniel R. Scoles - Salt Lake City UT, US
Gene Hung - San Diego CA, US
Assignee:
Ionis Pharmaceuticals, Inc. - Carlsbad CA
University of Utah Research Foundation - Salt Lake City UT
International Classification:
C12N 15/113
Abstract:
Disclosed herein are methods for decreasing Ataxin 2 mRNA and protein expression. Such methods are useful to treat, prevent, or ameliorate Ataxin 2 associated diseases, disorders, and conditions. Such Ataxin 2 associated diseases include spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), and parkinsonism. Provided are methods for reducing expression of Ataxin 2 (ATXN2) mRNA and protein in an animal. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases, including spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), and parkinsonism by inhibiting expression of Ataxin 2 in an animal.
Daniel R Scoles from Holladay, UT, age ~62 Get Report